Search

Inherited progressive sight loss is caused by a range of rare genetic conditions. We specialise in those which affect the retina.

We provide funding for innovative, high quality research projects investigating the causes and potential treatments for all forms of inherited retinal disease.

Making yourself aware of the what you are entitled to, and understanding the diagnosis pathway for inherited sight loss, will put you in a stronger position to seek better support.

Prof Dominic Ffytche will provide an explanation of what Charles Bonnet Syndrome is, the science behind it, and share some potential coping strategies for people who experience visual hallucinations.

• Webinar
• Video

Luxturna, a gene therapy, is only for the treatment of Leber congenital amaurosis type 2 (LCA2) and severe early-onset RP caused by mutations in a specific gene called RPE65.

• FAQ
• Written

Dr Graham undertook research into the basic mechanisms of retinal vasculitis, inflammation of the blood vessels in the retina, and is an important cause of poor vision in patients with uveitis, inflammation of the uveal tract.

• Trustee
• Written

Genes exist inside all the cells that make up your body. They contain genetic code (DNA) and provide instructions for constructing proteins, which are the building blocks of our bodies and perform a huge variety of roles.

Next month, Anisha and Sheena will take on The Thames Path Challenge. Together, they explain why they decided to join #TeamRetinaUK.

• News
• Retinitis pigmentosa

We talk to BBC reporter Ramadan Younes and Professor Robert Maclaren following the BBC documentary Blind Faith

• Podcast
• Audio

Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.

• News
• Retinitis pigmentosa